Summary: Analysis of mRNAs from liver biopsy samples of patients with chronic hepatitis C revealed that the levels of nuclear receptor expression were correlated with those of drug-metabolizing enzymes and transporters in relation to the development of fibrosis. Overall, the median mRNA level was largely dependent on fibrosis stage (F), and that for stage 3 patients (F3) was about 50% less than that for F1 patients. Levels of expression of AhR, together with CAR and PXR, were lowest in livers of F3 patients. Multivariate linear regression analysis revealed that AhR expression appeared to be involved in the regulation of CYP1A2, 2E1, 2D6, UGT1A, MDR1/3, MRP2/3, NTCP and OCT1 in the livers of patients with chronic hepatitis C. These results suggest that downregulation of AhR during the progression of liver fibrosis is associated with decreased expression levels of these phase I and II enzymes and drug transporters during inflammation-related signal transduction between AhR and other nuclear receptors.
Introduction
Hepatic expression of drug-metabolizing enzymes and transporters, which are heterogeneous in nature and influenced by many factors including genetics, disease and concomitant drug intake, is one of the major determinants of drug elimination capacity. Administration of individual probe drugs that are metabolized by specific cytochromes P450 ¤CYPs¥, such as the CYP3A-specific substrate midazolam, make it possible to relate hepatic drug metabolic capacity to liver function parameters using systems such as the ChildPugh score. Frye et al. recently administered probe drugs specific for the drug-metabolizing enzymes CYP1A2, -2C19, -2D6, and -2E1 to patients with various liver diseases, 1¥ and showed that liver disease severity had differential effects on their metabolic activity.
The levels of mRNA for several CYPs, such as CYP1A2, -2C, -2D6, and -3A4, but not CYP2E1, are well correlated with their protein levels and activities in patients with liver cirrhosis.
2,3¥ Recently, we have reported CYPs and drug transporter mRNA levels in patients with chronic hepatitis C. 4¥ As liver fibrosis progressed, the levels of the mRNAs encoding CYP1A2, -2E1, and -3A4, and Na ¦ -taurocholate cotransporting polypeptide ¤NTCP¥, organic anion transporting peptide-C ¤OATP-C¥, and organic cation transporter 1 ¤OCT1¥ show marked decreases, whereas that of the mRNA encoding tumor necrosis factor-AE ¤TNF-AE¥ increased. 4¥ Long-term hepatitis C virus ¤HCV¥ infection induces cellular oxidative stress including an increase of reactive oxygen species ¤ROS¥. 5¥ Waris et al. have reported that HCV infection induces endoplasmic reticulum ¤ER¥ stress through ER-nucleus signal transduction and activation of STAT-3 6¥ and nuclear factor kappa B ¤NFÏB¥, associated with production of proinflammatory cytokines such as TNF-AE, after infection with human immunodeficiency virus.
7¥ It has been proposed that the association of NFÏB ¤RelA¥ and activated aryl hydrocarbon receptor ¤AhR¥ proteins plays a role in the toxicity of dioxin. Furthermore, activation of AhR leads to repression of NFÏB-mediated transcription, 8¥ and AhR-mediated gene expression has been extensively investigated to clarify its biochemical and pathological roles. 9¥ Induction of CYP1A1 through AhR signaling upon treatment with dioxin is impaired in human hepatocarcinoma cells overexpressing non-structural protein ¤NS¥ 5A of HCV.
10,11¥ Thus, HCV infection and progression of the disease to a severer state probably affects drug metabolism and disposition capacity via alterations of nuclear receptor signaling, including AhR. In the present study, we used quantitative real-time PCR analysis to focus on the expression of nuclear factors such as the constitutive androstane receptor ¤CAR¥, pregnane X receptor ¤PXR¥, hepatocyte nuclear factor 4 AE ¤HNF4AE¥, peroxisomal proliferatoractivated receptor AE ¤PPARAE¥, nuclear factor-erythroid 2 p45-related factor 2 ¤NRF2¥, glucocorticoid receptor ¤GR¥, AhR, aryl hydrocarbon receptor nuclear translocator ¤ARNT¥ and NFÏB, which were not investigated extensively in our previous study, 4¥ to further establish their role in the regulation of CYPs and drug transporters in patients with chronic hepatitis C.
Materials and Methods
Subjects: Liver biopsy was performed in 63 patients with chronic hepatitis C at Toranomon Hospital, Tokyo, as reported previously. 4¥ Fibrosis staging and inflammation grading in these patients were determined according to the New Inuyama Classification by an independent pathologist. The clinicopathological characteristics of the patients are shown in Table 1 . We also collected clinical laboratory data on the day of liver biopsy, or on the preceding day. Some of the patients were taking prescribed drugs, but we considered these medications unlikely to influence the production of the enzymes under investigation. Eight of the liver biopsy samples were excluded because the RNA had been degraded through use of the Agilent 2100 Bioanalyzer ¤Agilent Biotechnologies, Japan¥, and a further 6 samples were excluded because of insufficient volume. The study was conducted in accordance with the Helsinki Declaration, and was approved by the ethics committee of Toranomon Hospital. Informed consent was obtained from all patients.
RNA extraction, reverse transcription, and realtime PCR: For the present study, we measured the levels of mRNA encoding CYP1A1, -2C8, -2C9, -2C19, -2D6, -3A4 and -3A5, and OATP-A, OATP-B, OATP-C, MDR1, MDR3, MRP1 and MRP3, and the newly determined nuclear receptors, CAR, PXR, HNF4AE, PPARAE, NRF2, GR, AhR, ARNT and NFÏB. cDNA from patients was prepared as reported previously. 4¥ cDNA amplification was performed with an ABI PRISM 7700 Sequence Detection System or 7300 Real Time PCR System ¤Applied Biosystems, Japan¥. We used real-time PCR to analyze the levels of mRNAs encoding drug-metabolizing enzymes, transporters, and nuclear-related proteins ¤Supplementary Table A¥ . Messenger RNA levels were normalized relative to those of GAPDH ¤glyceraldehyde-3-phosphate dehydrogenase¥ and Ç-actin. Human liver poly ¤A¥¦RNA ¤1 µg/µL, Lot#2070753, Becton Dickinson, Franklin Lakes, NJ, USA¥ was used as a standard for quantification of each mRNA. cDNA was prepared in the same way as described above, after the poly ¤A¥¦RNA had been diluted to 10,000, 2,000, 400, 80, 16, or 3.2 pg/µL. In the real-time PCR reaction, we used 2' TaqMan Universal PCR Master Mix ¤Applied Biosystems¥, which is optimized for TaqMan reactions. The primers and probe were designed and manufactured by Applied Biosystems ¤Supplementary Table A¥. The conditions for the thermal cycler were 50ôC for 2 min and 90ôC for 10 min, followed by 40 cycles at 95ôC for 15 s and 60ôC for 1 min. All amplification reactions were performed in duplicate. If the deviation between the duplicated data was greater than 50%, re-analysis was performed.
Statistical analysis: Statistical analysis was performed using the SPSS program ¤SPSS, Chicago, IL, USA¥. The 
Results
Relationships between relative expression of mRNAs encoding CYPs and transporters, and fibrosis stage and inflammation grade: With regard to fibrosis staging, the present patients with chronic HCV comprised 27 with F1, 9 with F2, 13 with F3, and none with F4; with regard to inflammation grading, 28 patients were A1, 21 were A2, and none were A3 ¤Table 1¥.
The expression levels of CYP2A6 and OATP-A were below the limit of quantification, and these data were therefore excluded from subsequent analysis.
The expression of mRNAs encoding CYP1A2, -2B6, -2C9, -2E1 and -3A4, and BSEP, MDR3, MRP2, NTCP, OAT2 and OATP-C was significantly lower in patients with stage F3 than in those with stage F1 ¤Table 2¥. Furthermore, the expression of mRNAs for CYP2E1 and -3A4, OATP-B, and OCT1 differed significantly between stage F1 and F2. Both CYP1A2 and -2C8 in stage F3 were significantly lower than those in stage F2. On the other hand, mRNA levels of CYP1A2, MRP2 and OATP-B were significantly affected by inflammation grade ¤Table 2¥. In order to clarify the relationship between changes in mRNA levels and the progression of fibrosis, we examined the median levels of mRNA expression ¤obtained from all data on the CYPs and transporters studied¥ at different stages of fibrosis ¤Fig. 1¥. Interestingly, the median mRNA level was highly correlated with fibrosis stage, that in F3 being about 50% less than that in F1. However, the ratio of the levels of mRNA for BCRP, MDR1 and MRP3 in stages F3 to F1 was higher than 0.85, suggesting that the expression of these genes was not affected by fibrosis progression.
Relationship between fibrosis stage and relative expression of mRNAs encoding nuclear receptors: The expression of mRNAs encoding CAR, PXR, and AhR was significantly lower in stage F3 patients than in F1 patients ¤Fig. 2¥. There were also significant correlations among nuclear receptors ¤Table 3¥. There was a strong correlation between the expression of mRNA for CAR and that for PXR in all F1 to F3 patients. The expression of mRNA for AhR was significantly correlated with that for PPARAE, NRF2, GR and ARNT. Although there was no correlation between PPARAE and HNF4AE, the expression of mRNA for PPARAE and that for HNF4AE in stage F3 were significantly correlated ¤r © 0.819; data not shown¥. The Each of the figures represents the level of statistical probability. We conducted multivariate linear regression analysis of data on the transcript levels of drug-metabolizing enzymes and transporters, using nuclear receptor expression levels and clinical laboratory parameters as covariates ¤Table 4¥. This revealed that the expression of CYP1A2, CYP2E1, NTCP, OCT1, CYP2D6, UGT1A, MDR1/3, MRP2/3, OAT2 and OATP-C was commonly correlated with that of AhR in the livers of patients with chronic hepatitis C. Among these, the hepatic levels of CYP1A2, CYP2E1, NTCP and OCT1 were lowest in F3 patients, reflecting the level of AhR. The expression of Fig. 2 . Typical relationships among relative expression levels of mRNAs for nuclear-associated receptors and stages of fibrosis CAR, constitutive androstane receptor; PXR, pregnane X receptor; AhR, aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor translocator; NRF2, nuclear factor-E2-related factor 2; GR, glucocorticoid receptor; HNF4¡, hepatocyte nuclear factor 4, alpha. PPARAE and PXR was also associated with that of CYP2B6, 2C8, 2C19, 3A4 and 3A5. On the basis of these results, a suggested relationship among CYPs, transporters and nuclear receptors is summarized in Figure 3 .
Discussion
The aim of this study was to assess the role of nuclear receptors in the hepatic expression of CYPs and transporters and its relationship with the development of fibrosis in patients with chronic hepatitis C.
Median mRNA expression levels in F3 patients ¤obtained using all data for the CYPs and transporters studied¥ were roughly half those in F1 patients, and were highly correlated with different stages of fibrosis ¤Fig. 1¥. Although the mechanisms of regulation differ, and large inter-individual variations exist, these results suggest overall downregulation of many CYPs and transporters with fibrosis progression.
The most important point to consider is what causes the decrease and inter-patient variation in expression of mRNAs for CYPs and transporters in patients with chronic hepatitis C. It is widely accepted that nuclear receptors and nuclear factors including CAR, PXR, AhR, and NRF2 are involved in the regulation of CYPs and drug transporters. We found that the levels of expression of mRNAs for CAR, PXR, and AhR were significantly lower in F3 patients than in F1 patients ¤Fig. 2¥. Although expression of the genes encoding CYP2B6, CYP2C9, and CYP3A4 is regulated by networks of nuclear steroid receptors, 12¥ there was no significant correlation between the expression of CYPs and that of CAR ¤Table 4¥. On the other hand, the expression of mRNAs for CYP2B6, 2C8, 2C19, 3A4 and 3A5 was highly correlated with that for PPARAE ¤Table 4¥. Our present results appear to suggest the presence of different regulatory networks for downregulation of CYPs and drug transporters, involving PXR, PPARAE, and AhR, in chronic hepatitis C. Recent data from drug transporter studies have provided some insight into the effect of chronic HCV infection on drug transporter regulation through nuclear receptors and nuclear factors. Jigorel et al. demonstrated that MDR1, MRP2, and BCRP were upregulated by treatment with phenobarbital ¤a CAR activator¥, rifampicin ¤a PXR activator¥, and oltipraz ¤an NRF2 activator¥ in cultured human hepatocytes.
13¥
They confirmed that these transporters are partly under PXR control. In the present study, expression of mRNAs for BSEP, MRP2, MRP3, OATP-B and OCT1 was also significantly correlated with PXR. Interestingly, the level of AhR mRNA was strongly correlated with almost all of the transporters studied, suggesting that AhR also regulates these transporters during the progression of fibrosis.
One important finding of the present study was the apparent downregulation of AhR during the progression of fibrosis. The mechanisms of CYP1A regulation by AhR have been extensively studied.
14,15¥ Expression of both CYP1A1 and CYP1A2 mRNA was significantly correlated with that of AhR, suggesting that a decrease in AhR results in a decrease in the biosynthesis of both CYPs in patients with chronic hepatitis C. Increases in the levels of bronchoalveolar lavage cell proinflammatory cytokines, TNF-AE and IL-6, and increased neutrophilia in the lungs of AhR-null mice following exposure to cigarette smoke or endotoxin have been reported. 16¥ On the other hand, activation of AhR has been reported to suppress NFÏB-mediated transcription through binding of NFÏB and AhR proteins. 8¥ Transcription factors including NFÏB, AP-1, STAT3 and C/EBP have been shown to be involved in transcriptional control of inflammatory signaling. 9¥ Therefore, downregulation of AhR may be associated with enhanced NFÏB signaling, and thus aggravation of inflammatory responses. In this study, a good correlation among nuclear receptors, especially GR, NFÏB, ARNT and PPARAE, was observed ¤Table 2¥. Cross-talk between nuclear receptors has been reported, and GR and PPARAE have been shown to interact and suppress the transcriptional activity of NFÏB.
17¥ NFÏB is also able to interact with the PXR-retinoid X receptor ¤RXR¥ complex, leading to downregulation of CYP3A4 gene expression by lipopolysaccharide. 18¥ A recent in vitro regulation study using primary human hepatocytes has shown that TNF-AE and interleukin-6 ¤IL-6¥ reduced the expression of mRNAs for sinusoidal transporters, including NTCP, OATP-B and OCT1. 19¥ Together with the findings of our previous study using HepG2 cells, which demonstrated a fibrosis-dependent increase in the level of TNF-AE mRNA and downregulation of NTCP and OCT1 by IL-6 and TNF-AE, 4¥ it can be concluded that increases in the levels of proinflammatory cytokines result in negative regulation of nuclear receptors, drug metabolizing enzymes, and drug transporters. In summary, a number of CYPs and drug transporters likely undergo downregulation during the progression of liver fibrosis, partly in association with downregulation of nuclear receptors and nuclear factors, including AhR, PXR and PPARAE. The expression of mRNA for AhR is highly correlated with that for CYP1A2, 2D6 and 2E1, and almost all of the transporters studied. Status of nuclear receptor ligands/activators should be evaluated in a future study. On the basis of the available data, we propose a gene expressionbased scheme for the relationships between the expression of various CYPs and drug transporters and that of nuclear receptors in patients with chronic hepatitis C, as illustrated in Figure 3 , which remains to be confirmed by further in vivo studies.
